CN111707827A - 一种乙型肝炎表面抗原检测试剂盒 - Google Patents
一种乙型肝炎表面抗原检测试剂盒 Download PDFInfo
- Publication number
- CN111707827A CN111707827A CN202010598229.5A CN202010598229A CN111707827A CN 111707827 A CN111707827 A CN 111707827A CN 202010598229 A CN202010598229 A CN 202010598229A CN 111707827 A CN111707827 A CN 111707827A
- Authority
- CN
- China
- Prior art keywords
- antibody
- hbsag
- solution
- buffer solution
- hepatitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000001514 detection method Methods 0.000 title claims abstract description 31
- 239000000427 antigen Substances 0.000 title claims abstract description 18
- 102000036639 antigens Human genes 0.000 title claims abstract description 18
- 108091007433 antigens Proteins 0.000 title claims abstract description 18
- 208000002672 hepatitis B Diseases 0.000 title claims abstract description 12
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims abstract description 23
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims abstract description 23
- 241000283707 Capra Species 0.000 claims abstract description 12
- 238000006243 chemical reaction Methods 0.000 claims abstract description 12
- 239000006249 magnetic particle Substances 0.000 claims abstract description 10
- 239000003550 marker Substances 0.000 claims abstract description 8
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 40
- 239000007853 buffer solution Substances 0.000 claims description 37
- 239000000243 solution Substances 0.000 claims description 35
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 30
- 238000002156 mixing Methods 0.000 claims description 24
- 241001494479 Pecora Species 0.000 claims description 17
- 238000002360 preparation method Methods 0.000 claims description 14
- 239000000047 product Substances 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 12
- 102000057297 Pepsin A Human genes 0.000 claims description 10
- 108090000284 Pepsin A Proteins 0.000 claims description 10
- 239000000872 buffer Substances 0.000 claims description 10
- 238000001976 enzyme digestion Methods 0.000 claims description 10
- 229940111202 pepsin Drugs 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
- 239000007983 Tris buffer Substances 0.000 claims description 9
- 239000007864 aqueous solution Substances 0.000 claims description 9
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 claims description 9
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 9
- 229920002684 Sepharose Polymers 0.000 claims description 7
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 6
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 6
- 150000001768 cations Chemical class 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 6
- 239000011780 sodium chloride Substances 0.000 claims description 6
- 239000000758 substrate Substances 0.000 claims description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 5
- 208000006454 hepatitis Diseases 0.000 claims description 5
- 231100000283 hepatitis Toxicity 0.000 claims description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 5
- 238000000746 purification Methods 0.000 claims description 5
- 239000008213 purified water Substances 0.000 claims description 5
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- ASVYXWZOBCRSFB-UHFFFAOYSA-N C(C)S(=O)(O)=S.OCCN1CCNCC1 Chemical compound C(C)S(=O)(O)=S.OCCN1CCNCC1 ASVYXWZOBCRSFB-UHFFFAOYSA-N 0.000 claims description 3
- XYIPYISRNJUPBA-UHFFFAOYSA-N [3-(3'-methoxyspiro[adamantane-2,4'-dioxetane]-3'-yl)phenyl] dihydrogen phosphate Chemical compound O1OC2(C3CC4CC(C3)CC2C4)C1(OC)C1=CC=CC(OP(O)(O)=O)=C1 XYIPYISRNJUPBA-UHFFFAOYSA-N 0.000 claims description 3
- 230000003213 activating effect Effects 0.000 claims description 3
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 3
- 238000000502 dialysis Methods 0.000 claims description 3
- 238000004090 dissolution Methods 0.000 claims description 3
- 238000010828 elution Methods 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 238000002372 labelling Methods 0.000 claims description 3
- 238000011068 loading method Methods 0.000 claims description 3
- 230000007935 neutral effect Effects 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- SZVJSHCCFOBDDC-UHFFFAOYSA-N ferrosoferric oxide Chemical compound O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 claims description 2
- 230000035945 sensitivity Effects 0.000 abstract description 20
- 230000009871 nonspecific binding Effects 0.000 abstract description 2
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 11
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 6
- 229920001213 Polysorbate 20 Polymers 0.000 description 5
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 5
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000003908 quality control method Methods 0.000 description 4
- 239000013558 reference substance Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000010998 test method Methods 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000008105 immune reaction Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 206010059193 Acute hepatitis B Diseases 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 240000003421 Dianthus chinensis Species 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 241000872931 Myoporum sandwicense Species 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000037628 acute hepatitis B virus infection Diseases 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000003904 radioactive pollution Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
- G01N33/5761—Hepatitis B
- G01N33/5764—Hepatitis B surface antigen
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/535—Production of labelled immunochemicals with enzyme label or co-enzymes, co-factors, enzyme inhibitors or enzyme substrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54326—Magnetic particles
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010598229.5A CN111707827B (zh) | 2020-06-28 | 2020-06-28 | 一种乙型肝炎表面抗原检测试剂盒 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010598229.5A CN111707827B (zh) | 2020-06-28 | 2020-06-28 | 一种乙型肝炎表面抗原检测试剂盒 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111707827A true CN111707827A (zh) | 2020-09-25 |
CN111707827B CN111707827B (zh) | 2023-12-29 |
Family
ID=72543110
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010598229.5A Active CN111707827B (zh) | 2020-06-28 | 2020-06-28 | 一种乙型肝炎表面抗原检测试剂盒 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111707827B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112924664A (zh) * | 2021-01-25 | 2021-06-08 | 华南理工大学 | 一种提高竞争elisa灵敏度的方法 |
CN113176412A (zh) * | 2021-04-07 | 2021-07-27 | 武汉艾迪康医学检验所有限公司 | 一种用于人白介素2可溶性受体的elisa检测方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030032008A1 (en) * | 2000-02-01 | 2003-02-13 | Kook-Jin Lim | DIagnostic reagents and methods for antibody against hepatitis b surface antigen and for antibody against hepatitis b virus |
CN101975859A (zh) * | 2010-09-13 | 2011-02-16 | 北京倍爱康生物技术有限公司 | 一种乙型肝炎病毒表面抗原的磁微粒分离化学发光免疫分析检测方法 |
CN104090106A (zh) * | 2014-07-21 | 2014-10-08 | 威海威高生物科技有限公司 | 乙型肝炎病毒表面抗原定量测定试剂盒及其制备方法 |
CN108344869A (zh) * | 2018-02-05 | 2018-07-31 | 苏州长光华医生物医学工程有限公司 | 一种乙肝表面抗原化学发光免疫检测试剂盒及其应用 |
-
2020
- 2020-06-28 CN CN202010598229.5A patent/CN111707827B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030032008A1 (en) * | 2000-02-01 | 2003-02-13 | Kook-Jin Lim | DIagnostic reagents and methods for antibody against hepatitis b surface antigen and for antibody against hepatitis b virus |
CN101975859A (zh) * | 2010-09-13 | 2011-02-16 | 北京倍爱康生物技术有限公司 | 一种乙型肝炎病毒表面抗原的磁微粒分离化学发光免疫分析检测方法 |
CN104090106A (zh) * | 2014-07-21 | 2014-10-08 | 威海威高生物科技有限公司 | 乙型肝炎病毒表面抗原定量测定试剂盒及其制备方法 |
CN108344869A (zh) * | 2018-02-05 | 2018-07-31 | 苏州长光华医生物医学工程有限公司 | 一种乙肝表面抗原化学发光免疫检测试剂盒及其应用 |
Non-Patent Citations (1)
Title |
---|
马莉: "乙型肝炎病毒表面抗原磁微粒发光法定量检测试剂盒的研发" * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112924664A (zh) * | 2021-01-25 | 2021-06-08 | 华南理工大学 | 一种提高竞争elisa灵敏度的方法 |
CN113176412A (zh) * | 2021-04-07 | 2021-07-27 | 武汉艾迪康医学检验所有限公司 | 一种用于人白介素2可溶性受体的elisa检测方法 |
Also Published As
Publication number | Publication date |
---|---|
CN111707827B (zh) | 2023-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111707827B (zh) | 一种乙型肝炎表面抗原检测试剂盒 | |
CN108344869B (zh) | 一种乙肝表面抗原化学发光免疫检测试剂盒及其应用 | |
CN105785043A (zh) | 用于定量检测afp-l3%的试剂盒 | |
AU613187B2 (en) | Method for increasing specificity in competitive immunoassays | |
JP2008216237A (ja) | 非特異反応を減少させた免疫診断薬 | |
CN109633180A (zh) | 一种游离睾酮化学发光检测试剂盒及其制备方法 | |
KR20040010589A (ko) | 면역 분석법 | |
CN101363861A (zh) | 乙型肝炎病毒表面抗原化学发光免疫分析测定试剂盒及其制备方法 | |
CN113433318A (zh) | 一种检测甲胎蛋白异质体afp-l3含量的试剂盒及其检测方法和应用 | |
CN106324254A (zh) | 一种抗胰岛素抗体检测试剂盒及其检测方法 | |
JP4197393B2 (ja) | IgA腎症の検査法 | |
CN110850085A (zh) | 异常凝血酶原化学发光免疫检测试剂盒及其制备方法 | |
JP6048923B2 (ja) | B型慢性肝炎の検出方法および検出キット | |
CN110672850A (zh) | 甲型肝炎病毒抗体IgM检测试剂盒及其制备方法 | |
JP2019053060A (ja) | B型肝炎ウイルスコア抗体の免疫測定方法 | |
Heinzel et al. | A new method for the quantitative determination of antibody and antigen protein, with a sensitivity to five micrograms | |
CN108333370A (zh) | 一种磁珠时间分辨荧光免疫定量检测cTnI试剂盒 | |
CN111175496A (zh) | 妊娠相关蛋白a磁微粒化学发光检测试剂盒及其使用方法 | |
CN112710842B (zh) | hsCRP检测试剂盒和hsCRP的检测方法 | |
US5210020A (en) | Immunoassay utilizing alginate to enhance signal to noise ratio | |
KR20010025027A (ko) | 면역측정시약 및 면역측정법 | |
US4226847A (en) | Latex polymer sensitized with steroid-serum albumin conjugate, preparation and test therewith | |
CN111707826B (zh) | 一种乙型肝炎表面抗体检测试剂盒 | |
FI78181C (fi) | Foerfarande, testfoerpackning och reagens foer immunokemisk bestaemning av hepatitis b kaernantigener. | |
JP3228791B2 (ja) | 検体中の抗原又は抗体の測定法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Address after: 300300 building 14, international medical device Industrial Park, No. 16, Wujing Road, economic and Technological Development Zone, Dongli District, Tianjin Applicant after: Tianjin boasaisi Biotechnology Co.,Ltd. Address before: No. 201, No. 10, Siwei Road, Dongli Development Zone, Dongli District, Tianjin Applicant before: BIOSCIENCE (TIANJIN) DIAGNOSTIC TECHNOLOGY Co.,Ltd. |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20231201 Address after: 300300 building 14, international medical device Industrial Park, No. 16, Wujing Road, economic and Technological Development Zone, Dongli District, Tianjin Applicant after: Tianjin boasaisi Biotechnology Co.,Ltd. Applicant after: BIOSYS (Chongqing) Biotechnology Co.,Ltd. Address before: 300300 building 14, international medical device Industrial Park, No. 16, Wujing Road, economic and Technological Development Zone, Dongli District, Tianjin Applicant before: Tianjin boasaisi Biotechnology Co.,Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant |